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The study was conducted to determine if serum copper
level could be a useful marker for selection for control
examinations and if serum copper level is a risk factor in
developing cancer.
Copper was quantitatively measured in diluted serum
samples by inductively coupled plasma mass spectrometry
(ICP-MS) using mass spectrometer (Elan DRC-e, Perki-
nElmer) in standard mode. In our study, there were two
independent groups of patients examined. In the first,
retrospective model, there were patients diagnosed with
prostate cancer (n = 166) and laryngeal cancer (n = 123)
matched with healthy controls. This study showed that
serum copper level above 1250 µg/l may be a useful mar-
ker for laryngeal examination, but is not a useful marker
for prostate cancer early detection. In the second, prospec-
tive model, there were patents diagnosed with breast can-
cer (n = 42) matched with unaffected controls. Serum
from breast cancer patients was collected 3 - 41 months
before cancer diagnosis. This part of study showed that
there is a tendency that breast cancer risk is about two
times lower when copper serum level is in range between
1035 - 1311 µg/l. Further investigations are needed.
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